Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. The U.S. Food and Drug Administration campus in ...

FILE - The U.S. Food and Drug Administration campus in Silver Spring, Md., is photographed on Oct. 14, 2015. (AP Photo/Andrew Harnik, File) 31,129 people played the daily Crossword recently. Can ...

So JOURNAVX is a NaV1.8 inhibitor ... We have initiated these conversations with the FDA, but we haven't concluded them. We're going to have our end of Phase 2 meeting this summer, and I expect ...

(RTTNews) - As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. From January through May 2025, the U.S. regulatory agency has approved 13 novel drugs ...

BiVacor announced today that it received FDA breakthrough device designation for its Total Artificial Heart (TAH) system. The designation supports the TAH as a bridge to transplant (BTT ...

Journavx, a sodium-channel inhibitor that blocks pain signals, is effective but non-addictive, and is the first new class of pain medication approved by the US Food and Drug Administration (FDA ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases.

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain.

The big bet here is Journavx, a non-opioid acute pain treatment poised for FDA approval by early 2025. Analysts are optimistic, banking on strong demand and Medicare’s NOPAIN Act, which practically ...